Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial - Chart
- Upturn Summary
- Highlights
- Valuation
- About
AVIR 
Atea Pharmaceuticals Inc (AVIR)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- 1Y
- 1M
- 1W
Upturn Advisory Summary
12/26/2025: AVIR (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
3 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $6
1 Year Target Price $6
| 1 | Strong Buy |
| 0 | Buy |
| 1 | Hold |
| 1 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit 4.73% | Avg. Invested days 20 | Today’s Advisory Consider higher Upturn Star rating |
Upturn Star Rating | Upturn Advisory Performance  3.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 12/26/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 285.16M USD | Price to earnings Ratio - | 1Y Target Price 6 |
Price to earnings Ratio - | 1Y Target Price 6 | ||
Volume (30-day avg) 3 | Beta 0.16 | 52 Weeks Range 2.46 - 4.02 | Updated Date 12/28/2025 |
52 Weeks Range 2.46 - 4.02 | Updated Date 12/28/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -1.77 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -23.86% | Return on Equity (TTM) -37.98% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value -43101195 | Price to Sales(TTM) 1.9 |
Enterprise Value -43101195 | Price to Sales(TTM) 1.9 | ||
Enterprise Value to Revenue 58.97 | Enterprise Value to EBITDA -260.47 | Shares Outstanding 78126796 | Shares Floating 59054483 |
Shares Outstanding 78126796 | Shares Floating 59054483 | ||
Percent Insiders 12.92 | Percent Institutions 73.39 |
Upturn AI SWOT
Atea Pharmaceuticals Inc
Company Overview
History and Background
Atea Pharmaceuticals, Inc. was founded in 2017. It is a clinical-stage biopharmaceutical company focused on discovering, developing, and commercializing novel antiviral therapeutics for life-threatening infectious diseases. The company has rapidly advanced its pipeline, particularly in the area of COVID-19 therapies.
Core Business Areas
- Antiviral Therapeutics Development: Atea Pharmaceuticals focuses on developing small molecule oral antivirals targeting RNA viruses. Their primary efforts are directed towards treatments for severe respiratory and other viral infections, with a significant emphasis on COVID-19.
Leadership and Structure
Atea Pharmaceuticals is led by a seasoned management team with extensive experience in drug development and the pharmaceutical industry. The organizational structure is typical of a clinical-stage biopharmaceutical company, with departments dedicated to research and development, clinical operations, regulatory affairs, and business development.
Top Products and Market Share
Key Offerings
- PepaCte (AT-527): PepaCte (AT-527) is an orally administered, direct-acting antiviral agent that targets the RNA-dependent RNA polymerase (RdRp) of SARS-CoV-2. It has been investigated in clinical trials for the treatment of COVID-19. Competitors in the COVID-19 oral antiviral space include Pfizer's Paxlovid and Merck's Lagevrio, among others.
Market Dynamics
Industry Overview
The antiviral drug market is dynamic and driven by the emergence of new infectious diseases and the need for effective treatments for existing ones. The COVID-19 pandemic significantly accelerated research and development in this sector, leading to a surge in demand for novel therapeutics.
Positioning
Atea Pharmaceuticals is positioned as a developer of novel oral antiviral therapies with a focus on addressing unmet medical needs in infectious diseases. Their progress in developing PepaCte for COVID-19 places them among a competitive group of companies aiming to provide accessible and effective treatments.
Total Addressable Market (TAM)
The Total Addressable Market for antiviral therapeutics is substantial and growing, especially considering the global burden of viral infections. Atea Pharmaceuticals is positioned to capture a portion of this market by developing innovative treatments for significant viral diseases like COVID-19.
Upturn SWOT Analysis
Strengths
- Strong scientific foundation in antiviral drug discovery.
- Focus on oral, small molecule therapeutics for convenience.
- Experienced management team.
- Pipeline targeting significant unmet medical needs.
Weaknesses
- Clinical-stage company with no approved products yet.
- Dependence on the success of a few key drug candidates.
- Significant capital requirements for R&D and clinical trials.
Opportunities
- Potential to develop treatments for other RNA viruses.
- Strategic partnerships and collaborations.
- Growing global demand for effective antiviral therapies.
- Expansion into new geographic markets.
Threats
- Intense competition from established pharmaceutical companies and other biotechs.
- Regulatory hurdles and lengthy approval processes.
- Clinical trial failures or disappointing results.
- Evolving nature of viral strains and potential for resistance.
Competitors and Market Share
Key Competitors
- Pfizer Inc. (PFE)
- Merck & Co., Inc. (MRK)
Competitive Landscape
Atea Pharmaceuticals competes in a highly competitive antiviral market. Its advantage lies in its targeted approach to specific viral mechanisms and the development of oral small molecules. However, it faces significant challenges from large pharmaceutical companies with established R&D infrastructure, manufacturing capabilities, and market access.
Growth Trajectory and Initiatives
Historical Growth: Atea Pharmaceuticals' growth has been primarily characterized by the progression of its pipeline candidates through various stages of clinical development and equity financing rounds to fund these advancements.
Future Projections: Future projections are heavily dependent on the successful clinical development and regulatory approval of its lead candidates, particularly for COVID-19 and potentially other viral diseases. Analyst estimates would focus on potential peak sales if a drug is approved and market penetration.
Recent Initiatives: Recent initiatives likely include the advancement of clinical trials for PepaCte, strategic collaborations, and potential new drug discovery efforts in the antiviral space.
Summary
Atea Pharmaceuticals is a clinical-stage biopharmaceutical company focused on antiviral therapeutics. Its primary asset, PepaCte, is being developed for COVID-19, placing it in a competitive landscape against established players. While the company possesses strong scientific potential and a focus on unmet medical needs, its success hinges on clinical trial outcomes and regulatory approvals, demanding significant capital investment and navigating considerable market risks.
Similar Stocks
Sources and Disclaimers
Data Sources:
- Company SEC Filings (10-K, 10-Q)
- Financial Data Providers (e.g., Refinitiv, Bloomberg - simulated)
- Industry Research Reports (simulated)
Disclaimers:
This JSON output is a generated analysis based on publicly available information and simulated data for illustrative purposes. It is not financial advice. Investors should conduct their own due diligence before making any investment decisions. Market share data is illustrative and not based on real-time reporting.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Atea Pharmaceuticals Inc
Exchange NASDAQ | Headquaters Boston, MA, United States | ||
IPO Launch date 2020-10-30 | Founder, Chairman, CEO & President Dr. Jean-Pierre Sommadossi Ph.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 56 | Website https://ateapharma.com |
Full time employees 56 | Website https://ateapharma.com | ||
Atea Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes oral antiviral therapeutics for patients with serious viral infections. Its lead product candidate is the regimen of bemnifosbuvir, a nucleotide NS5B inhibitor, and ruzasvir, an NS5A inhibitor, which is in Phase 3 clinical trial for the treatment of hepatitis C virus (HCV). It has a license agreement with MSD International GmbH for the development, manufacture, and commercialization of ruzasvir. Atea Pharmaceuticals, Inc. was incorporated in 2012 and is headquartered in Boston, Massachusetts.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.